Novo’s Wegovy pill thesis continues to bear out in 2026, as the oral obesity med keeps impressive sales apace while sparing ...

On Tuesday, Novo reported its quarterly results which showed that Wegovy pill generated sales of 3.22 billion Danish kroner ...

News of the unconfirmed deal talks drew major investor pushback on AZ’s side, with the British drugmaker’s stock sliding nearly 9% following the Financial Times report. The company’s London-listed ...

Gilead Sciences’ HIV prevention business reached a milestone, exceeding $1 billion in quarterly sales for the first time. | ...

Before she transitioned from the PR side to the pharma advertising side, Publicis CoLab group account supervisor Brielle Hoffman found herself “itching” for more creative work.  | Hoffman wanted to be ...

In closing out the TDF/TAF litigation chapter, Gilead is simultaneously moving to a new era of HIV treatment altogether with ...

As Amgen’s flagship PCSK9 cholesterol drug Repatha enjoys a bit of a renaissance on the back of impressive cardiovascular ...

Long viewed as one of the biggest hype-to-disappointment stories in pharmaceutical history, the PCSK9 cholesterol drug class ...

After a yearslong struggle, Jazz Pharmaceuticals has called time on Zepzelca as a second-line treatment for small cell lung cancer. | After a yearslong struggle, Jazz Pharmaceuticals has called time ...

It’s been years since Big Pharma last witnessed a megamerger. In the late 2010s, Takeda bought Shire, AbbVie acquired ...

Growth of new drugs and a steady base business helped Bayer weather expected declines across Xarelto and Eylea sales in Q2, ...

Johnson & Johnson has named Tom Cavanaugh as the next leader of its innovative medicines business, beginning Sept. 1, 2026.